142 related articles for article (PubMed ID: 22543914)
41. Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women.
Chishti U; Aziz AB
J Pak Med Assoc; 2015 Mar; 65(3):306-9. PubMed ID: 25933567
[TBL] [Abstract][Full Text] [Related]
42. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602.
Onda T; Matsumoto K; Shibata T; Sato A; Fukuda H; Konishi I; Kamura T; Yoshikawa H;
Jpn J Clin Oncol; 2008 Jan; 38(1):74-7. PubMed ID: 18258715
[TBL] [Abstract][Full Text] [Related]
43. [Paclitaxel/carboplatin in first line treatment of advanced ovarian carcinoma].
Meerpohl HG
Praxis (Bern 1994); 1999 Mar; 88(12):513-8. PubMed ID: 10235026
[TBL] [Abstract][Full Text] [Related]
44. [PET/CT scan with (18)F-FDG in re-staging of an atypical case of ovarian cancer].
García Gómez FJ; Cuenca Cuenca JI; Acevedo Báñez I; Borrego Dorado I; Calvo García E; Vázquez Albertino RJ
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):223-4. PubMed ID: 23067691
[No Abstract] [Full Text] [Related]
45. [Paclitaxel + carboplatin (TC)-resistant stage Ic squamous cell carcinomas arising in mature cystic teratomas of the ovary].
Ishikawa M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Miyazaki K
Gan To Kagaku Ryoho; 2010 Apr; 37(4):747-52. PubMed ID: 20414041
[TBL] [Abstract][Full Text] [Related]
46. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
47. Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect.
Salvinelli F; Casale M; Vincenzi B; Santini D; Di Peco V; Firrisi L; Onori N; Greco F; Tonini G
J Exp Clin Cancer Res; 2003 Mar; 22(1):155-8. PubMed ID: 12725337
[TBL] [Abstract][Full Text] [Related]
48. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
49. [Decision-making of treatment and relative problems about recurrent and drug-resistant gynecologic neoplasms].
Xie X; Cheng XD
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):801-3. PubMed ID: 21211274
[No Abstract] [Full Text] [Related]
50. [Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
Dartigues P
Ann Pathol; 2015 Aug; 35(4):327-37. PubMed ID: 26210689
[No Abstract] [Full Text] [Related]
51. Paclitaxel and carboplatin treatment for advanced ovarian cancer during pregnancy.
Ruiz Ramos J; Roma E; Palomar L; Poveda JL
Chemotherapy; 2013; 59(5):344-5. PubMed ID: 24820861
[TBL] [Abstract][Full Text] [Related]
52. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
53. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Colombo N; Peiretti M; Garbi A; Carinelli S; Marini C; Sessa C;
Ann Oncol; 2012 Oct; 23 Suppl 7():vii20-6. PubMed ID: 22997450
[No Abstract] [Full Text] [Related]
54. [The results of ovarian cancer therapy in the Hungarian Centers in 2002-2003].
Pulay T; Baki M; Bodoky G; Dank M; Cseh J; Csejtei A; Csömör S; Erfán J; Esik O; Faluhelyi Z; Izsó J; Hernádi Z; Kammerer K; Magyar T; Mayer A; Megyery E; Moskovits K; Pécsi L; Pikó B; Pintér T; Ruzsa A; Szánthó A; Szántó I; Szántó J; Szucs M; Tálos Z; Thurzó L; Kásler M
Orv Hetil; 2006 Dec; 147(52):2493-500. PubMed ID: 17294573
[TBL] [Abstract][Full Text] [Related]
55. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E
Gynecol Oncol; 2011 Aug; 122(2):226-32. PubMed ID: 21575983
[TBL] [Abstract][Full Text] [Related]
56. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
57. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of ovarian cancer.
Ann Oncol; 2001 Sep; 12(9):1205-7. PubMed ID: 11697825
[No Abstract] [Full Text] [Related]
58. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
Gronlund B; Høgdall C; Christensen IJ; Engelholm SA; Hansen HH
Gynecol Oncol; 2004 Aug; 94(2):409-15. PubMed ID: 15297181
[TBL] [Abstract][Full Text] [Related]
59. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
[TBL] [Abstract][Full Text] [Related]
60. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
